Vedanta Biosciences (VE202 microbiome) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Vedanta Biosciences (VE202 microbiome) General Information

Description

Bacterial product meant to treat inflammatory bowel diseases. The microbiome pharmaceutical candidate, VE202, is a mix of bacteria from the Clostridia subspecies that could be a treatment for Crohn's disease and ulcerative colitis. It will will help either replenish or rejuvenate a type of immune cell called regulatory T-cells, which help the body cool off inflammation.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • Boston, MA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vedanta Biosciences (VE202 microbiome) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vedanta Biosciences (VE202 microbiome)‘s full profile, request access.

Request a free trial

Vedanta Biosciences (VE202 microbiome) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vedanta Biosciences (VE202 microbiome)‘s full profile, request access.

Request a free trial